Login

Ingredients

Omega-3 fatty acids

One of the most studied supplements in the world, with consistent small effects on inflammatory markers, modest reductions in cardiovascular events, measurable benefits for strength and executive function, and a clear negative result in advanced eye disease 123.

Last scientifically reviewed: November 22, 2026Editorial review: MDS Labs. External scientific review pending.

Commercial disclosure. MDS Labs sells an omega-3 EPA and DHA supplement. Everything on this page applies to it, including the AREDS2 finding and the bleeding-time caution.

Common names
Omega-3; fish oil; marine omega-3; EPA and DHA; ALA from plant sources
Source
Oily fish and fish oil, algal oil for EPA and DHA; flaxseed, walnuts and rapeseed for ALA
Part used
Not applicable: extracted oils
Key constituents
Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are the forms used in almost all the trials cited here; alpha-linolenic acid (ALA) from plants converts to them only poorly
Classification
Long-chain polyunsaturated fatty acids
Traditional use
Cod liver oil has a long history of use in northern Europe
US regulatory status
Dietary supplement; a purified prescription form also exists

Human evidence, outcome by outcome

Graded per outcome. A strong result for one outcome says nothing about another.

Inflammatory markers: CRP, IL-6 and TNF-alpha

Established in humans

All three markers were significantly reduced, with small to moderate effect sizes, and the reviewers concluded omega-3 can be recommended as an adjuvant anti-inflammatory agent 1.

Studied: An umbrella analysis pooling 32 separate meta-analyses across a range of health conditions.

Limits: Lowering a marker is not the same as improving an outcome, and pooling across many conditions makes the average less informative for any one situation.

Cardiovascular events

Limited human evidence

Marine omega-3 supplementation was associated with lower risk of myocardial infarction (RR 0.92), coronary heart disease death (RR 0.92), total coronary heart disease (RR 0.95), cardiovascular death (RR 0.93) and total cardiovascular disease (RR 0.97) 2.

Studied: 13 randomized trials in 127,477 participants over a mean treatment duration of 5.0 years, analysed excluding the REDUCE-IT trial.

Limits: These are small relative reductions. A risk ratio of 0.97 for total cardiovascular disease means a 3% relative reduction, which translates into a very modest absolute change for most individuals.

Progression to advanced age-related macular degeneration

Evidence against

Adding omega-3 fatty acids to the AREDS formulation did not further reduce progression to advanced age-related macular degeneration 3.

Studied: The AREDS2 randomized trial in people already at risk of advanced disease.

Limits: A direct negative in the population where a benefit was most plausible. Eye-health products containing omega-3 are not supported by this trial.

Executive function in adults without dementia

Limited human evidence

The benefit landed specifically on executive function, the planning-and-switching side of thinking, and built gradually over roughly the first 12 months 4.

Studied: 24 trials covering 9,660 adults without dementia, followed between three months and three years.

Limits: Nothing dramatic and nothing quick. A short trial of omega-3 for memory would be expected to find nothing, and several have.

Muscle strength and walking function in sarcopenia

Limited human evidence

More than 2.5 g a day produced the largest improvements in upper-body strength and lower-body physical function, and the effects held in trials with no resistance training attached 5.

Studied: A network meta-analysis of 16 randomized trials in people with sarcopenia or at high risk of it.

Limits: No omega-3 regimen significantly increased skeletal muscle mass, and the confidence interval on the strength result runs from close to zero to very large 5.

A pattern of small, real effects

Omega-3 is unusual in this field: it has been tested in enormous numbers of people across several unrelated outcomes, and it keeps producing the same kind of answer. Something real, consistently in the same direction, and small.

That is a more credible profile than a supplement with one spectacular result, and it is also a reason to keep expectations proportionate. A 3% relative reduction in total cardiovascular disease 2 is a genuine population-level finding and a barely perceptible individual one.

The eye result is worth knowing

Omega-3 is widely sold for eye health, often alongside lutein and zeaxanthin. The AREDS2 trial tested exactly that addition in people already at risk of advanced macular degeneration and found it did not further reduce progression 3.

This is the clearest negative on the page, in the population where a benefit should have been easiest to detect.

The one place it works without exercise

In the muscle research, almost everything depends on a training stimulus. Omega-3 is the exception: at more than 2.5 g a day its effects on strength and walking function held up in a separate analysis of trials with no resistance training programme attached 5.

For someone who genuinely cannot train, that makes it the one option on the strength page with evidence of working unaided. It did not increase muscle mass, so people got stronger without getting bigger.

How closely our product matches what was studied

MDS Labs sells Omega-3+ Softgels at 180 mg EPA and 120 mg DHA, which is 300 mg of combined EPA and DHA per softgel. Measured against the research on this page, that figure deserves stating directly rather than leaving the reader to work it out.

The sarcopenia findings required more than 2.5 g a day of omega-3 5, an amount this product does not reach at one or two softgels. The cardiovascular trials generally used around a gram of combined EPA and DHA daily 2. Anyone taking omega-3 for the outcomes described above should therefore compare the combined EPA and DHA total against what the trials used, rather than counting softgels or reading the total oil weight on the front of any bottle, ours included.

We sell it because the published research on the compound is worth following, which is a different statement from a claim about what it will do for you.

What we can conclude

Omega-3 is a reasonable, well-tolerated supplement with modest benefits spread across inflammation, cardiovascular risk, strength and executive function, and a documented failure in advanced eye disease 3. Nothing here justifies dramatic claims, and the consistency across very large trials is its real strength.

Dose matters more than most labels suggest: the muscle findings required more than 2.5 g a day 5, which is above what many products provide per serving.

Technical layer: chemistry and pharmacokinetics

EPA, DHA and ALA. The trials cited here almost all used marine EPA and DHA. Alpha-linolenic acid from flaxseed and similar sources converts to EPA and DHA only inefficiently in humans, so evidence generated with fish or algal oil does not transfer automatically to plant-derived products.

Reading the label. The figure on the front of a fish oil bottle is often the total oil per capsule rather than the combined EPA and DHA content, which is the number the trials dosed on. Checking the EPA plus DHA total is the single most useful habit when comparing products, particularly against the above-2.5 g daily amounts used in the sarcopenia research 5.

Bleeding time. Higher doses affect bleeding time, which matters for anyone taking anticoagulant or antiplatelet medication and for anyone scheduled for surgery. This is a pharmacist conversation rather than a reason for blanket avoidance.

Back to Top
Added to cart
Your Cart
0
Close

No products in the cart.